查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511910

抗糖尿病药物市场规模、份额和趋势分析报告：按药物类别、类型、给药途径、分销管道、地区和细分市场预测，2024-2030年

Antidiabetics Market Size, Share & Trends Analysis Report By Drug Class (GLP-1 Receptor Agonists, Insulin), By Type (Type 1, Type 2), By Route of Administration (Oral, Intravenous), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

抗糖尿病药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2023年至2030年全球抗糖尿病药物市场规模将以12.23%的复合年增长率增长，2030年将达到1844.7亿美元。

糖尿病盛行率的增加是该市场的主要驱动因素。不规则的饮食习惯和日益增加的肥胖预计也会透过诱发目标疾病的发生率来推动产品需求。目前正在研发的产品的未来商业化以及亚太和拉丁美洲新兴市场存在的重大开拓机会预计将在未来几年推动市场成长。

胰岛素是盈利最高的细分市场，2013年市场规模超过200亿美元。胰岛素也是这个市场上最赚钱的细分市场之一。推出具有更高功效的新产品以及存在有利的政府倡议是增加市场吸引力的因素。

抗糖尿病药物市场报告亮点

  • 新核准的DPP-4 抑制剂，如 Januvia、Nesina 和 Onglyza，因其每日一次的给药方案和安全性而迅速渗透到市场。
  • 北美是最成熟的抗糖尿病药物市场，2023年占市场份额为41.51%。的市场成长。
  • 预计亚太地区将为製造商提供有利的未来成长机会。大量未满足的需求和快速改善的医疗基础设施是预计推动该地区市场成长的因素之一。当地製造商推出廉价产品也预计将推动市场发展。
  • 抗糖尿病药物的主要市场参与者包括阿斯特捷利康公司、拜耳公司、工业公司、勃林格殷格翰公司、百时美施贵宝公司、默克公司、强生服务公司、辉瑞公司。
  • 该市场本质上是寡占，少数公司控制着70%以上的市场。对新产品开发的广泛研发投资以及透过政府合约进入新兴市场是这些公司采取的关键永续性策略。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势及展望
  • 市场动态
    • 糖尿病发生率上升
    • 研究和技术进步
    • 提高认识和早期疗育
  • 市场限制因素分析
    • 开发成本高
    • 副作用和安全问题
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章 药品类别业务分析

  • 降血糖药市场：药品类别波动分析
  • 胰岛素
  • GLP-1受体促效剂
  • DPP-4抑制剂
  • SGLT2抑制剂
  • DPP-4抑制剂
  • 其他的

第五章依糖尿病类型分類的业务分析

  • 抗糖尿病药物市场：依糖尿病类型波动分析
  • 类型1
  • 2型

第六章依途径进行的业务分析

  • 抗糖尿病药物市场：给药途径变化分析
  • 口服
  • 皮下的
  • 静脉

第七章 通路业务分析

  • 抗糖尿病药物市场：通路波动分析
  • 网路药房
  • 医院药房
  • 零售药房

第八章区域业务分析

  • 2022年及2030年按地区分類的抗糖尿病药物市场占有率
  • 北美洲
    • SWOT分析
    • 北美抗糖尿病药物市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • SWOT分析
    • 欧洲抗糖尿病药物市场，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • SWOT分析
    • 亚太地区抗糖尿病药物市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲抗糖尿病药物市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • SWOT分析
    • 2018-2030年中东及非洲抗糖尿病药物市场
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 公司分类
  • 策略规划
  • 2022 年企业市场占有率分析
  • 公司简介/上市公司
    • AstraZeneca plc
    • Bayer AG
    • Takeda Pharmaceutical Company Limited
    • Eli Lilly and Company
    • Boehringer Ingelheim
    • Bristol-Myers Squibb Company
    • Pfizer, Inc.
    • Johnson &Johnson Services Inc.
    • Merck &Co. Inc
    • Novartis AG
Product Code: 978-1-68038-304-1

Antidiabetics Market Growth & Trends:

The global antidiabetics market size is expected to reach USD 184.47 billion by 2030, expanding at a CAGR of 12.23% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of diabetes is the primary driver of this market. Growth in irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue-generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. The introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Antidiabetics Market Report Highlights:

  • The rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina, and Onglyza on account of their once-daily dosage regimens and safety profiles catalyzed the growth of this market.
  • North America was the most mature antidiabetics market in 2023 accounting for over 41.51% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.
  • Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.
  • Some key market players of antidiabetics include AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co. Inc, Johnson & Johnson Services Inc. and Pfizer.
  • The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Drug Class Segment
      • 1.1.1.2. Diabetes Type Segment
      • 1.1.1.3. Distribution Channel Segment
      • 1.1.1.4. Route of Administration Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Rising Diabetes Prevalence
    • 3.4.2. Advancements in Research and Technology
    • 3.4.3. Increasing Awareness and Early Intervention
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Development Costs
    • 3.5.2. Side Effects and Safety Concerns
  • 3.6. Industry Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Drug Class Business Analysis

  • 4.1. Antidiabetics Market: Drug Class Movement Analysis
  • 4.2. Insulin
    • 4.2.1. Insulin Market, 2018 - 2030 (USD Million)
      • 4.2.1.1. Insulin Market, By Type
      • 4.2.1.1.1. Long-acting insulin
      • 4.2.1.1.1.1. Long-acting insulin market, 2018 - 2030 (USD Million)
      • 4.2.1.1.2. Premix insulin
      • 4.2.1.1.2.1. Premix insulin market, 2018 - 2030 (USD Million)
      • 4.2.1.1.3. Fast-acting insulin
      • 4.2.1.1.3.1. Fast-acting insulin market, 2018 - 2030 (USD Million)
      • 4.2.1.1.4. Human insulin
      • 4.2.1.1.4.1. Human insulin market, 2018 - 2030 (USD Million)
  • 4.3. GLP-1 Receptor Agonists
    • 4.3.1. GLP-1 Receptor Agonists Market, 2018 - 2030 (USD Million)
  • 4.4. DPP- 4 Inhibitors
    • 4.4.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.5. SGLT2 Inhibitors
    • 4.5.1. SGLT2 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.6. DPP-4 Inhibitors
    • 4.6.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Diabetes Type Business Analysis

  • 5.1. Antidiabetics Market: Diabetes Type Class Movement Analysis
  • 5.2. Type 1
    • 5.2.1. Type 1 Market, 2018 - 2030 (USD Million)
  • 5.3. Type 2
    • 5.3.1. Type 2 Market, 2018 - 2030 (USD Million)

Chapter 6. Route of Administration Business Analysis

  • 6.1. Antidiabetics Market: Route of Administration Movement Analysis
  • 6.2. Oral
    • 6.2.1. Oral Market, 2018 - 2030 (USD Million)
  • 6.3. Subcutaneous
    • 6.3.1. Subcutaneous Market, 2018 - 2030 (USD Million)
  • 6.4. Intravenous
    • 6.4.1. Intravenous Market, 2018 - 2030 (USD Million)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. Antidiabetics Market: Distribution Channel Movement Analysis
  • 7.2. Online Pharmacies
    • 7.2.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospital Pharmacies, Market, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Antidiabetics Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. SWOT Analysis
    • 8.2.2. North America Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. U.S. Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Canada Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. SWOT Analysis
    • 8.3.2. Europe Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. UK Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.4. Germany
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Germany Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. France Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Italy Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Spain Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Denmark Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Sweden Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Norway Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. SWOT Analysis
    • 8.4.2. Asia Pacific Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Japan Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. China Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. India Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Australia Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Thailand Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.8. South Korea
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. South Korea Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. SWOT Analysis
    • 8.5.2. Latin America Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Brazil Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Mexico Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.5.5. Argentina
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Competitive Scenario
      • 8.5.5.4. Regulatory Framework
      • 8.5.5.5. Argentina Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. South Africa Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Saudi Arabia Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. UAE Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Competitive Scenario
      • 8.6.6.4. Regulatory Framework
      • 8.6.6.5. Kuwait Antidiabetics Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Company Profiles/Listing
    • 9.4.1. AstraZeneca plc
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Bayer AG
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Takeda Pharmaceutical Company Limited
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Eli Lilly and Company
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Boehringer Ingelheim
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Bristol-Myers Squibb Company
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Pfizer, Inc.
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Johnson & Johnson Services Inc.
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Merck & Co. Inc
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Novartis AG
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global antidiabetics market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 Global antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 4 Global antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 Global antidiabetics market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 North America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 10 North America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 North America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 U.S. antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 14 U.S. antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 U.S. antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Canda antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 18 Canada antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Canada antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 22 Europe antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 23 Europe antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Europe antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 UK antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 UK antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 27 UK antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 Germany antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 30 Germany antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 31 Germany antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Germany antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 France antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 France antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 35 France antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 France antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Italy antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Italy antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 39 Italy antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Italy antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Spain antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 Spain antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 43 Spain antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Spain antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 46 Denmark antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 47 Denmark antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Denmark antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 50 Sweden antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 51 Sweden antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Sweden antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Norway antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 54 Norway antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 55 Norway antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Norway antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Japan antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 63 Japan antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 64 Japan antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 Japan antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 China antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 67 China antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 68 China antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 China antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 India antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 71 India antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 72 India antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 India antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Australia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 75 Australia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 76 Australia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 77 Australia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Thailand antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 79 Thailand antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 80 Thailand antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 81 Thailand antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 South Korea antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 83 South Korea antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 84 South Korea antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 South Korea antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Latin America antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 87 Latin America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 88 Latin America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 89 Latin America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 92 Brazil antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 93 Brazil antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 94 Brazil antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Mexico antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 96 Mexico antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 97 Mexico antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 Mexico antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 100 Argentina antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 101 Argentina antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 Argentina antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 109 South Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 110 South Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 111 South Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 117 UAE antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 118 UAE antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 119 UAE antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 123 Kuwait antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Antidiabetics market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global antidiabetics market: drug class movement analysis
  • Fig. 16 Global antidiabetics market, for Insulin, 2018 - 2030 (USD Million)
  • Fig. 17 Global antidiabetics market, for GLP-1 receptor agonists, 2018 - 2030 (USD Million)
  • Fig. 18 Global antidiabetics market, for DPP- 4 inhibitors, 2018 - 2030 (USD Million)
  • Fig. 19 Global antidiabetics market, for SGLT2 inhibitors, 2018 - 2030 (USD Million)
  • Fig. 20 Global antidiabetics market, for others, 2018 - 2030 (USD Million)
  • Fig. 21 Global antidiabetics market: diabetes type movement analysis
  • Fig. 22 Global antidiabetics market, for type 1, 2018 - 2030 (USD Million)
  • Fig. 23 Global antidiabetics market, for type 2, 2018 - 2030 (USD Million)
  • Fig. 24 Global antidiabetics market: route of administration movement analysis
  • Fig. 25 Global antidiabetics market, for oral, 2018 - 2030 (USD Million)
  • Fig. 26 Global antidiabetics market, for subcutaneous, 2018 - 2030 (USD Million)
  • Fig. 27 Global antidiabetics market, for intravenous, 2018 - 2030 (USD Million)
  • Fig. 28 Global antidiabetics market: distribution channel movement analysis
  • Fig. 29 Global antidiabetics market, for online pharmacies, 2018 - 2030 (USD Million)
  • Fig. 30 Global antidiabetics market, for hospital pharmacies, 2018 - 2030 (USD Million)
  • Fig. 31 Global antidiabetics market, retail pharmacies, 2018 - 2030 (USD Million)
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional outlook, 2022 & 2030
  • Fig. 34 Global antidiabetics market: region movement analysis
  • Fig. 35 North America antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 40 UK antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 41 France antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 49 China antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 50 India antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait antidiabetics market, 2018 - 2030 (USD Million)